Novartis Sticks With Bolt-Ons As Biotech Bubble Bursts

Rather than major M&A, CEO Vas Narasimhan has told Scrip that Novartis will carry on doing development and licensing deals and while the firm has noted that the valuations of prospective biotech deals have fallen, "they still remain relatively high."